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ABSTRACT
Objectives: Intrahepatic cholestasis of pregnancy (ICP) is significantly more often associated with an abnormal perinatal 
outcome compared to a group of healthy pregnant women. 
The aim of the study was to analyse the correlation between the adverse perinatal outcome and the biochemical parameters 
in pregnancy complicated by cholestasis, and to assess their predictive value for neonatal complications.
Material and methods: Eighty-six patients with ICP were divided into 3 groups according to their fasting serum bile acid 
level [group I n = 60, 10–39.90 μmol/L; group II n = 20, 40–99.90 μmol /L; group III n = 6, TBA (total bile acids) ≥ 100.00 μmol/L]. 
Linear regression models were created to determine the relation of serum TBA, ALT, and AST concentration with total adverse 
perinatal outcome, defined as an occurrence of at least one perinatal outcome: stillbirth, preterm birth, spontaneous and 
iatrogenic preterm birth, presence of meconium in amniotic fluid, Apgar score (< 7 in 5th min), pH from umbilical artery  
(< 7.1), necessity for NICU admission, the presence of breathing disorders, and the need to perform phototherapy.
Results: TBA ≥ 40.00 μmol/L is connected to an elevated risk of the occurrence of total adverse perinatal outcome (OR = 4.17, 
p = 0.0037, AUC = 0.62, p = 0.046). TBA ≥ 40.00 μmol/L is a predictor of preterm birth (OR 2.3, p = 0.0117), iatrogenic preterm 
birth (OR 2.5, p = 0.006), admission to NICU (OR 2.38, p = 0.0094), intubation or assisted ventilation (OR 2.16, p = 0.0301), and 
phototherapy (OR 2.0, p = 0.0438). The threshold value of TBA for the need for phototherapy was 52.7 μmol/L (AUC = 0.67, 
p = 0.0089) and for preterm birth, 32.1 μmol/L (AUC = 0.62, p = 0.0251).
Conclusions: Pregnant women with ICP and TBA serum level over 40.00 μmol/L have a worse prognosis regarding obstetric 
outcomes. The concentration of bile acids is a predictor of the occurrence of adverse perinatal outcomes, although the 
concentration of ALT and AST failed to show such a connection.
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INTRODUCTION
The birth of a healthy, full-term newborn is the most 
important goal for every obstetrician. This task becomes 
a challenge especially if the pregnant woman, who was com-
pletely healthy, becomes ill during pregnancy. Intrahepatic 
cholestasis of pregnancy (ICP) is an illness that emerges in 
1% of pregnant women in the second or at the beginning of 
the third trimester [1]. Cholestasis of pregnancy is the most 
common liver disorder occurring during pregnancy, with 
symptoms most commonly subsiding shortly after birth [2]. 
It is a benign liver condition, however, due to the itching 
that occurs at night, it can be troublesome for a pregnant 
woman [3]. Cholestasis is manifested by elevated serum bile 
acid (TBA, total bile acids) and aminotransferases levels. In 
fewer than 10% of cases, cholestasis is accompanied with 
jaundice [4]. Although the disease is benign for the pregnant 
woman, it may be very dangerous for the foetus, because 
it is significantly more often associated with an abnormal 
perinatal outcome, including stillbirth as the most serious 
one, compared to a group of healthy pregnant women [5]. 
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Among other negative events for the newborn resulting 
from cholestasis, we observe spontaneous and iatrogenic 
preterm birth, a worse postnatal condition evaluated on 
the basis of the pH of the umbilical cord blood and Apgar 
score, hypoxia, the presence of meconium in the amniotic 
fluid, and admission to a neonatal intensive care unit (NICU) 
[6]. Despite numerous hypotheses (placenta microstructure 
disorders, foetal arrhythmia), the mechanism increasing the 
risk of such complications, including stillbirth in cholestasis 
patients, has not been identified yet. Also, no therapies 
preventing this complication exist [7–9]. The meta-analyses 
carried out so far have led to a conclusion that the occur-
rence of adverse obstetrics outcomes, including stillbirth, 
is associated with the concentration of bile acids in the 
pregnant woman [10]. Kawakita et al. [11] demonstrated 
that a concentration of TBA ≥100 μmol/L is correlated with 
the risk of stillbirth, and a concentration ≥ 40.0 μmol/L is 
correlated with the presence of meconium in the amniotic 
fluid. Based on the meta-analysis carried out by Glanza et 
al., it can be concluded that cholestasis with a concentration 
of bile acids < 40.00 μmol/L will not impact the increase in 
risk of foetal complications [12]. However, Chen et al. [13] 
have shown that an adverse obstetric outcome is affected 
by a concentration of TBA ≥ 57.55 μmol/L. The mentioned 
neonatal complications occur unpredictably, without any 
perceivable preceding symptoms. Currently, the only tool 
for assessing the risk of an abnormal perinatal outcome 
is the evaluation of the concentration of bile acids in the 
pregnant woman’s serum.
Aim of the study
The aim of the study was to analyse the correlation be-
tween the adverse perinatal outcome and the biochemical 
parameters in pregnancy complicated by cholestasis, and 
to assess their predictive value for neonatal complications.
MATERIALS AND METHODS
Patients
The analysis included 86 patients with diagnosed In-
trahepatic Cholestasis of Pregnancy (ICP), hospitalised 
in the Gynaecological and Obstetrics Clinical Hospital of 
Poznan University of Medical Science (GPSK). The research 
was conducted from January 2017 until December 2018. The 
protocol of the study was approved by the Bioethics Com-
mittee of the Poznan University of Medical Sciences of 
Karol Marcinkowski in Poznań (1062/16/01.12.2016 and 
197/18/01.02.2018). An informed written consent was ob-
tained from each of the patients participating in the study. 
The intrahepatic cholestasis of pregnancy was diag-
nosed on the basis of clinical symptoms (presence of itchi-
ness without skin changes) and abnormal laboratory tests 
results: elevated concentration of TBA in the serum meas-
ured in fasting blood ≥ 10.00 μmol/L, and concentration of 
aminotransferases: alanine aminotransferase (ALT) > 33 U/L, 
aspartate aminotransferase (AST) > 32.00 U/L [14]. The ex-
clusion criteria included: other conditions causing pruritus, 
chronic/acute liver and bile duct diseases (viral or autoim-
mune hepatitis, primary biliary cholangitis, acute fatty liver, 
obstructive jaundice, cholecystolithiasis), pre-eclampsia, 
HELLP syndrome. Each of the women who qualified to par-
ticipate in the study were Caucasian.
The pregnant women with ICP were divided into 
three groups, based on the fasting bile acid levels in the 
serum, reflecting the severity of the illness. Group I, with 
TBA concentration of 10–39.90 μmol/L, n = 60 (69.77%) 
with mild cholestasis, group II — TBA 40–99.90 μmol/L, 
n = 20 (23.25%) presenting ICP with medium severity, and 
group III — TBA ≥ 100.00 μmol/L, n = 6 (6.98%), comprised 
of patients suffering from severe cholestasis (Tab. 1) [5].
Treatment
After the diagnosis of cholestasis, all patients were treat-
ed with ursodeoxycholic acid (UDCA), starting with a dose 
of 250 mg three times a day. The medicine’s dose was modi-
fied subject to the lack of therapeutic effect when treated 
with a minimal dose (intensified itchiness reported by the 
patient, elevated TBA level), every few days. The maximal 
applied dose did not exceed 1500 mg/day. 
The concentration of bile acids and aminotransferases 
was monitored twice a week, or daily, in selected cases.
Every pregnant woman had cardiotocography done four 
times a day and ultrasonography, along with evaluation of 
blood flows in the foetal vessels once or twice a week.
Blood from pregnant women suspected of cholestasis 
was collected from the ulnar vein. The evaluation of bile 
acids, aminotransferases and bilirubin was performed in 
GPSK Central Laboratory. 
Termination of pregnancy was planned based on TBA 
levels and the week of pregnancy when cholestasis was diag-
nosed. In the case of mild cholestasis (TBA < 40.00 μmol/L), 
the birth took place following the recommendations of 
PTGiP (the Polish Society of Gynaecologists and Obstetri-
Table 1. Characteristics of patients with cholestasis of pregnancy
Analysed variable Examined group
Quantity 86
Age [years] 30 (22–46)a
Gravidity (number of past pregnancies) 1 (1–6)a
TBA 10–39.9 μmol/L n = 60 (69.77%)
TBA 40–99.9 μmol/L n = 20 (23.25%)
TBA ≥ 100 μmol/L n = 6 (6.98%)
amedian (range)
271
Milena Guszczynska-Losy et al., Bile acid in cholestasis complicated pregnancy
www. journals.viamedica.pl/ginekologia_polska
cians), after the foetus’ lungs have matured after the 38th 
week of pregnancy [15]. With TBA ≥ 100.00 μmol/L, the 
termination of pregnancy took place following the stimula-
tion of maturity of the foetus’ lungs, after the 34th week of 
pregnancy, and with TBA 40–99.9 μmol/L — after the 36th 
week of gestation. Depending on the level of cervix matu-
ration, labour was preinduced with 3 g of dinoprostone in 
cervical gel or a Foley’s catheter, while oxytocin in infusion 
pump was used for induction, as per GPSK scheme (5 IU 
oxytocin with 49 ml of solvent (0.9% NaCl or 5% glucose), 
infusion starts at 3 mL/h flow, increased by 0.5 mL/h every 
30 minutes, up to 6 mL/h).
In the absence of favourable prognostic conditions for nat-
ural labour, the pregnancy was ended by caesarean delivery.
Laboratory examination
The concentration of aminotransferases and the total 
serum bile acid levels were measured using the electro-
chemiluminescence method on a Cobas 6000 apparatus 
(Roche, Basel, Switzerland).
Analysed perinatal outcomes
The following obstetrics outcomes were analysed for 
the specified groups of patients: the total adverse perinatal 
outcome, stillbirth, preterm birth, spontaneous preterm 
birth, iatrogenic preterm birth, presence of meconium in 
the amniotic fluid, Apgar score (< 7 in 5th minute), pH from 
the umbilical artery (< 7.10), the necessity for NICU admis-
sion, the presence of breathing disorders, and the need to 
perform phototherapy.
The occurrence of at least one of the above analysed 
perinatal outcomes was considered a total adverse perinatal 
outcome. 
Statistical analysis
For ROC curve analysis, MedCalc Software (Ostend, Bel-
gium) was used. SigmaStat version 3.5 software (Systat Soft-
ware, Inc., Point Richmond, CA, USA) was used for statistical 
analysis. The results were analysed using the Mann-Whitney 
rank sum test for variables with a non-parametric distribu-
tion. Linear regression models were created to determine 
the relationship of serum TBA, ALAT, AspAT concentration 
with selected obstetric failures. The Chi-square test and the 
Fisher Exact Test were used for the assessment of the distri-
bution of the tested characteristics. P < 0.05 was considered 
statistically significant.
RESULTS
Perinatal outcomes
The analysed groups of pregnant women did not differ 
in terms of demographics. The average time in which chol-
estasis occurred, both mild and severe, was the 33rd week of 
pregnancy. However, biochemical parameters, such as TBA, 
AST and ALT concentration, differed significantly statistically 
between the groups of pregnant women with a mild form 
and those with a severe form of cholestasis. (Tab. 2)
The patients with TBA ≥ 40.00 μmol/L gave birth on 
average two weeks earlier in relation to women with mild 
cholestasis, which was a statistically significant difference 
(36th vs 38th week, p = 0.0087). No statistically significant 
differences in the manner of pregnancy termination, the 
percentage of multiple pregnancies, birth weight in the 
percentage of newborns, whose weight was lower than the 
10th and the 3rd percentile were found in both groups of 
patients. In the examined group of pregnant women with 
cholestasis, 67 had a single pregnancy, 18 had a twin preg-
nancy and one had a triplet pregnancy.
Total adverse perinatal outcome 
Among the analysed group of 86 pregnant women 
with intrahepatic cholestasis, an adverse perinatal outcome 
was found in 50 women, which included 31 of 60 women 
(52%) with mild cholestasis, and 19 of 26 women (73%) with 
a severe form of the illness. This difference was statistically 
significant (p = 0.0076). An adverse obstetrics outcome 
applied to 42 of 72 (58%) newborns from mothers with 
TBA < 40.00 μmol/L, and 26 of 34 (76%) newborns from 
mothers with TBA concentrations ≥ 40.00 μmol/L. 
No stillbirths and no newborn deaths occurred with any 
of the patients in the examined groups.
In the group with severe cholestasis, pregnancies ended 
prematurely significantly more often than in the group with 
Table 2. Demographic and laboratory characteristic of pregnant women with mild and severe cholestasis
TBA < 40.0 μmol/L n=60 TBA ≥ 40 μmol/L n=26 p value
Age [years] mean ± SD 31 ± 4 31 ± 5 0.904
Gravidity, median (range) 1 (1–6) 2 (1–4) 0.287
Gestational age at diagnosis [weeks], median (range) 33 (20–39) 33 (13–39) 0.723
TBA at diagnosis [μmol/L], median (range) 17.1 (7.9–37.3) 66.3 (40.1–171.3) < 0.001
AST at diagnosis [U/L], median (range) 97.95 (16.7–339.2) 167.9 (28.7–695.2) 0.026
ALT at diagnosis [U/L],  median (range) 183.4 (13.5–620.8) 276.7 (29.6–1228.9) 0.034
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mild cholestasis (54% vs 23%, p = 0.0055). In both groups, 
the decision to terminate gestation before term was more 
frequent than the occurrence of premature spontaneous de-
livery, and was 62% and 86%, respectively, for patients with 
a TBA concentration of < 40.00 μmol/L and ≥ 40.00 μmol/L. 
The newborns from mothers with severe cholestasis were 
hospitalised in NICU compared significantly to the new-
borns of mothers with mild cholestasis (5 days vs 4 days, 
p = 0.0472) and required phototherapy more often (38% vs 
15%, p = 0.0066). However, the necessity to apply ventila-
tion, the occurrence of breathing disorders, the presence 
of meconium in the amniotic fluid, the Apgar score in 5th 
minute, and the number of newborns born with a pH from 
umbilical artery of < 7.10 did not differ between the groups 
(Tab. 3).
Biochemical markers
Total adverse perinatal outcome 
The average TBA concentration in the group of preg-
nant women with an adverse perinatal outcome was 
statistically significantly higher in relation to the women 
with a normal obstetrics outcome, and was, respectively, 
45.2 ± 40.5 vs. 25.7 ± 15.3; p = 0.0028. This correlation was 
confirmed for single pregnancies p = 0.042. No statistical 
differences were found in the Aspat and Alat concentra-
tions between women with adverse and normal obstetrics 
outcomes.
Based on the conducted analysis, it was found that, in the 
group with more severe cholestasis (TBA ≥ 40.00 μmol/L), 
the chance of the occurrence of a total adverse perinatal 
outcome is 4.17 times higher than in relation to the group 
with mild cholestasis (p = 0.037) (Tab. 4). This relationship 
was separately confirmed for single pregnancies (OR 3.79, 
p = 0.0127), but no dependence was found for multiple 
pregnancies (p = 0.9838) (Tab. 4a). The predictive accuracy 
of the TBA concentration (> 40.1 μmol/L) for a total adverse 
perinatal outcome was confirmed by means of a ROC curve 
(p = 0.046) (Tab. 5).
Preterm births
The analysis of the relation of elevated TBA 
(≥ 40.00 μmol/L) with the occurrence of preterm (iatrogenic 
and spontaneous) birth shown a statistically significant rela-
tionship (OR 2.3, p = 0.0117) in relation to pregnant women 
Table 3. Perinatal outcomes of patients with mild and severe cholestasis
TBA < 40.0 μmol/L; n = 60 TBA ≥ 40 μmol/L; n = 26 p value
Gestation age at delivery [weeks], median (range) 38 (31–41) 36 (29–39) 0.0087a
Multiple pregnancy, n (%) 12 (20%) 7 (27%) 0.669b
Birthweight [g], mean ± SD 2942 ± 639 2688 ± 771 0.0770c
Birthweight (percentile) < 10 percentile 6 (8%) 2 (6%) 0.6687b
< 3 percentile 4 (5%) 0 N/A
Route of delivery, n (%)
Vaginal 21 (35%) 15 (58%) 0.0501b
Caesarean section 33 (55%) 10 (38%) 0.1589b
Vacuum 6 (10%) 1 (4%) 0.3378b
Total adverse perinatal outcome (n) 31 patients (52%)42 newborns (58%)
19 patients (73%)
26 newborns (76%)
0.0076b
0.0581b
Stillbirths 0 0
Preterm delivery < 37th week of gestation (n) (%) 14 (23%) 14 (54%) 0.0055b
Spontaneous (n) (%) 5 (38%) 2 (14%) 0.3845d
Iatrogenic (n) (%) 9 (62%) 12 (86%)
NICU admission (n) (%), 23 (32%) 17 (50%) 0.0660b  
NICU length of stay [days], median (range) 4 (3–42) 5 (3–90) 0.0472 a
Ventilation (n) (%) or intubation 11 (15%) 10 (29%) 0.082b
Phototherapy (n) (%) 11 (15%) 13 (38%) 0.0066b
Breathing problems (n) (%) 14 (19%) 11 (32%) 0.1337b
Presence of meconium — stained amniotic fluid (n) (%) 7 (10%) 8 (24%) 0.0531b
Apgar score < 7 at 5th min. after birth (n) (%) 2 (3%) 1 (3%) 0.9531b
Umbilical arterial pH < 7.10 (n) (%) 1 (1%) 1 (3%) 0.2111b
aMann-Withney Rank Sum Test; bchi Sqare; cStudent U-test; d2 × 2 Fisher Exact test
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with a lower TBA concentration. The chance of preterm 
labour for a single pregnancy was 2.9 (p = 0.0259), but this 
dependence was not confirmed for multiple pregnancies 
(p = 0.3041) (Tab. 4a). Based on the ROC curve analysis, it was 
found that a TBA concentration of > 32.0 μmol/L is an opti-
mal predictive factor of preterm labour (p = 0.0251) (Tab. 5).
Iatrogenic preterm birth
Higher concentration of TBA (≥ 40.00 μmol/L) was a sig-
nificant predictive factor for iatrogenic preterm birth, OR 
2.5, p = 0.006 (Tab. 4). This correlation was confirmed for 
single pregnancies OR 4.2, p = 0.0082, whereas a higher TBA 
concentration was not a predictor of pregnancy ending in 
multiple pregnancies (p = 0.3082) (Tab. 4a).
Newborn admission to NICU
For the group with the most severe cholestasis, TBA 
was a predictor for admitting the newborn to the neona-
tal intensive care unit (OR 2.38, p = 0.0094) (Tab. 4). The 
chance of admission of a neonate born by a mother with 
a TBA of ≥ 40.00 μmol/L to NICU for a single pregnancy was 
2.6 times higher than for newborns born by mothers with 
a low TBA concentration (p = 0.0373). This dependence was 
not confirmed with multiple pregnancies p = 0.2026 (Tab. 4a).
The use of intubation or ventilation
The correlation of TBA concentration with the use of 
ventilation showed a statistically significant difference be-
tween the analysed groups (p = 0.0301). For newborns born 
by mothers with more severe cholestasis, the chances of 
the necessity of ventilation were almost twice as high OR 
2.16 (Tab. 4).
The use of phototherapy
The chances for the necessity of phototherapy for new-
borns from patients with a higher TBA concentration was 
twice as high as for mothers with a mild form of cholesta-
sis OR 2.0, which was a statistically significant correlation 
p = 0.0438 (Tab. 4). Based on the ROC curve analysis, it was 
found that a concentration of TBA ≥ 52.70 μmol/L is a predic-
tive factor of phototherapy p = 0.0089 (Tab. 5).
Breathing disorders
TBA concentration was not a predictor of the occurrence 
of breathing disorders, p = 0.0634 (Tab. 4).
Presence of meconium in amniotic fluid
There was no correlation between the concentration 
of TBA and the presence of meconium in amniotic fluid, 
p = 0.1361 (Tab. 4). 
The concentration of neither AST nor ALT was a predic-
tive factor of any of the analysed adverse perinatal out-
comes.
DISCUSSION
In the present study, the correlation of bile acid and 
aminotransferases levels with an adverse perinatal out-
come in 86 pregnant women with intrahepatic cholesta-
sis of pregnancy was analysed. Our study has shown that 
pregnant women with a TBA of ≥ 40.00 μmol/L serum level 
experienced an adverse obstetrics result significantly more 
often than pregnant women with a lower TBA concentration. 
In the group of patients suffering from severe choles-
tasis, over 70% of the women and 76% of the newborns 
experienced adverse perinatal outcomes, including preterm 
labour, the presence of meconium in the amniotic fluid, ad-
mission of the newborn to NICU, the necessity to intubate, 
and the use of phototherapy. Our results are consistent with 
the data presented by other authors. In 2017, Cui et al. pre-
sented a meta-analysis of 1,928 patients with cholestasis of 
pregnancy, in which they assessed the relationship between 
Table 4. OR for predictors of adverse perinatal outcomes in 
intrahepatic cholestasis of pregnancy
Adverse perinatal 
outcome Predictor OR 95% CI p value
Total adverse 
perinatal outcome
TBAa 4.17 1.59–10.93 0.0037
ASTb 0.71 0.48–1.39 0.4468
ALTc 0.74 0.39–1.40 0.3509
Preterm births 
TBAa 2.3 1.21–4.49 0.0117
ASTb 0.84 0.39–1.79 0.649
ALTc 0.78 0.44–1.40 0.4048
Iatrogenic preterm 
births
TBAa 2.5 1.30–4.85 0.006
ASTb 0.95 0.42–2.11 0.8922
ALTc 0.90 0.50–1.64 0.7423
Admission to NICU
TBAa 2.38 1.24–4.58 0.0094
ASTb 1.46 0.63–3.39 0.3815
ALTc 2.72 0.90–2.99 0.4723
Ventilation
TBAa 2.16 1.08–4.34 0.0301
ASTb 1.28 0.44–3.76 0.6512
ALTc 1.34 0.61–2.91 0.4647
Phototherapy
TBAa 2.00 1.02–3.93 0.0438
ASTb 1.06 0.41–2.75 0.9014
ALTc 0.89 0.47–1.71 0.7338
Breathing disorders
TBAa 1.88 0.97–3.68 0.0634
ASTb 1.22 0.47–3.21 0.6805
ALTc 1.23 0.61–2.45 0.5612
Presence of 
meconium in 
amniotic fluid
TBAa 1.98 0.81–4.86 0.1361
ASTb 2.27 0.37–14.06 0.3791
ALTc 2.49 0.62–10.05 0.2005
aReference category is 0–39.9 μmol/L; bReference category is 0 ≤ 40 IU/L; 
cReference category is 0 ≤ 40 IU/L
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the TBA serum level and the risk of an abnormal perinatal 
result. The authors concluded that an increase of the TBA 
level to ≥ 40.00 μmol/L is related to a significantly increased 
risk of the occurrence of a total abnormal perinatal outcome, 
preterm labour, the presence of meconium in amniotic fluid, 
hypoxia, and breathing disorders in newborns [6].
Table 5. Results of ROC curves analysis of TBA predictive values for negative neonatal outcomes
Adverse 
perinatal 
outcome
AUC  
[95% CI]
Cut Off 
[μmol/L]
Sensitivity 
(true positive 
rate) [95% CI]
Specificity (true 
negative rate) 
[95% CI]
Positive 
likelihood 
ratio
Negative 
likelihood 
ratio
Positive 
predictive 
value
Negative 
predictive 
value
p
Total adverse 
perinatal outcome
0.62  
[0.51–0.71] 40.1 41.43 [29.8–53.8] 87.88 [71.8–96.5] 3.42 0.67 87.9 41.4 0.046
Phototherapy 0.67  [0.58–0.76] 52.7 54.17 [32.8–74.4] 84.34 [74.7–91.4] 3.46 0.54 50.0 86.4 0.0089
Preterm births 0.62  [0.53–0.72] 32.1 55.56 [40.0–70.3] 72.58 [59.8–83.1] 2.03 0.61 59.5 69.2 0.0251
Table 4a. OR for predictors of adverse perinatal outcomes in intrahepatic cholestasis divided on single and multile of pregnancy
Adverse perinatal outcome Predictor
Single pregnancy Multiple pregnancy
OR 95% CI P value OR 95% CI P value
Total adverse perinatal outcome
TBAa 3.79 1.33–10.82 0.0127 1.01 0.32–4.57 0.9838
ASTb 0.44 0.17–1.13 0.0884 n/ad
ALTc 0.60 0.3–1.21 0.1551 n/ad
Preterm births 
TBAa 2.91 1.17–7.40 0.0259 2.17 0.46–9.50 0.3041
ASTb 0.39 0.16–0.94 0.0364 n/a
ALTc 0.53 0.24–1.18 0.1212 0.59 0.12–2.77 0.4998
Iatrogenic preterm births
TBAa 4.20 1.45–12.12 0.0082 1.73 0.60–4.93 0.3082
ASTb 0.50 0.19–1.31 0.1565 n/ad
ALTc 0.90 0.35–2.33 0.8296 0.29 0.06–1.38 0.1196
Admission to NICU
TBAa 2.60 1.06–6.38 0.0373 2.09 0.67–6.52 0.2026
ASTb 1.14 0.42–3.06 0.7957 0.3705 0.09–1.44 0.1536
ALTc 1.30 0.57–3.2 0.5032 n/ad
Ventilation
TBAa 2.16 1.08 – 4.34 0.0301 0.80 0.11–5.96 0.8298
ASTb 1.28 0.44 – 3.76 0.6512 0.59 0.15–2.31 0.4509
ALTc 1.34 0.61 0–2.91 0.4674 1.02 0.52–4.12 0.9825
Phototherapy
TBAa 1.05 0.4–2.8 0.916 2.24 0.83–6.0 0.1095
ASTb 0.99 0.37–2.64 0.9833 1.37 0.41–4.54 0.604
ALTc 0.63 0.3–1.32 0.2239 n/ad
Breathing disorders
TBAa 1.60 0.58–4.46 0.3671 1.96 0.75–5.16 0.1717
ASTb 0.95 0.31–2.87 0.9245 0.58 0.03–10.08 0.7108
ALTc 1.24 0.47–3.27 0.6695 0.96 0.31–2.96 0.9424
Presence of meconium in amniotic fluid
TBAa 1.7 0.33–6.47 0.6089 2.55 0.66–9.76 0.1732
ASTb n/ad 0.33 0.02–1.19 0.4611
ALTc 1.84 0.27–2.37 0.5294 3.36 0.38–30.08 0.2779
aReference category is 0–39.9 μmol/L; bReference category is 0 ≤ 40 IU/L; cReference category is 0 ≤ 40 IU/L; dnot applicable. All patients represented the same category
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In our study, we found a significantly higher percent-
age of preterm births in the group of patients with more 
severe cholestasis. In a study of 106 pregnant women with 
cholestasis, Chen et al. showed that a concentration of 
TBA ≥ 40.15 μmol/L is connected to an almost fourfold 
increased risk of preterm delivery as compared to pregnant 
women whose TBA concentration is lower than this value. 
In pregnancies complicated with cholestasis, the number 
of preterm births grows with the increase of the concentra-
tion of bile acids [16]. The results from collective data from 
meta-analyses also indicate an elevated risk of spontaneous 
preterm delivery (OR = 3.47) and iatrogenic preterm delivery 
in pregnant women with cholestasis [5].
In our research, the high percentage of preterm births 
was due to the high rate of occurrence of iatrogenic preterm 
labours for both TBA concentration ranges, and was, respec-
tively, 62% and 68% for the group with mild and severe chol-
estasis. Such high percentages of interventions result from 
the high proportion of multiple pregnancies (20% and 27%, 
respectively, in the group with mild and severe cholestasis), 
and, or primarily to avoid the most serious complication of 
cholestasis, which is intrauterine foetal death. None of the 
patients with cholestasis who gave birth in GPSK during 
this period had intrauterine foetal death or neonatal death. 
In 2019, Ovadia et al. published a meta-analysis of data 
5557 patients with intrahepatic cholestasis of pregnancy, 
concerning the relationship of bile acid serum concentration 
with stillbirth. Interpretation of the results obtained allowed 
the formulation of conclusions that only a concentration of 
bile acids of over 100.00 μmol/L is related to an increased risk 
of stillbirth [5]. The risk of intrauterine foetal death increases 
regardless of pregnancy advancement. The concentration 
of bile acids does not exceed 100.00 μmol/L in most of the 
pregnant women suffering from cholestasis. In this group of 
patients, the risk of stillbirth is comparable with the risk for 
the general population of pregnant women, in both ranges, 
40–100 μmol/L, and < 40 μmol/L.
The group of 6 pregnant women whose bile acid con-
centrations exceeded 100.00 μmol/L seems, from a clinical 
perspective, the most interesting one. The average age in 
that group was 29.6 years (28–32 years). For five of them, 
it was the second pregnancy, and only one woman had 
cholestasis in the previous pregnancy. In this group, two 
patients were in twin pregnancy. Two patients gave birth 
in completed the 37th week of pregnancy, and four prema-
turely (respectively, in the 31st, 33rd, 34th, and 36th week of 
pregnancy). In this group of patients, the average TBA serum 
concentration was 135.20 μmol/L (102.00–171.30 μmol/L), 
AST 230.77 U/L (36.00–350.60 U/L), ALT 356.72 U/L (52.30– 
–521.90 U/L). Caesarean section was performed on 5 of 
the 6 patients. Although the presence of meconium in the 
amniotic fluid was present twice, all newborns had normal 
pH in the umbilical cord blood (> 7.3) and the Apgar score in 
5th minute ranged from 7 to 10. Three newborns were admit-
ted to NICU: the twins born in the 31st week due to breathing 
disorders and the necessity to apply mechanical ventilation, 
and one of the twins from the 33rd week for the same rea-
son. These three newborns also required phototherapy. In 
both twin pregnancy cases, the decision to terminate the 
pregnancy was based on very high concentrations of bile 
acids, which increased despite treatment. In the pregnancy 
which ended in the 31st week of pregnancy, HELLP syndrome 
developed additionally. 
In our study, neonatal problems significantly more often 
concerned babies of mothers with severe cholestasis. These 
newborns were significantly more frequently prematurely 
born, stayed longer in NICU and required phototherapy 
more often. Similar results were presented by Garcia-Flores 
et al. [17] who, in a group of 52 newborns from 47 preg-
nant women with cholestasis, found significantly more fre-
quent adverse neonatal outcomes, including the presence 
of meconium in the amniotic fluid, admission to NICU, and 
neonatal global morbidity. 
Our analysis of the relation between adverse obstetrics 
outcomes and serum bile acids and aminotransferases level 
showed that a TBA concentration of over 40.00 μmol/L is 
connected to an elevated risk of the occurrence of total 
adverse perinatal outcome (OR = 4.17, p = 0.0037, AUC 0.62, 
p = 0.046). A TBA of ≥ 40.00 μmol/L was also a predictor of 
preterm labour, iatrogenic preterm labour, admission to 
NICU, intubation, assisted ventilation, and phototherapy. 
The correlation was confirmed for single pregnancies, but 
was not visible in multiple pregnancies, probably due to 
the small number of patients within the group. In the paper 
from 2017, Chen et al. [13] showed that a concentration of 
TBA ≥ 57.55 μmol/L was a significant predictor of the oc-
currence of an adverse obstetrics outcome (OR = 3.214). 
The results obtained by Celik et al. [18] show that both pre-
term births and admission to NICU take place significantly 
more often if the concentration of TBA in the serum exceeds 
34.00 μmol/L. Our analysis of ROC curves showed that a TBA 
of > 32.00 μmol/L was a significant predictor of preterm 
delivery, while a TBA of > 52.70 μmol/L was a significant pre-
dictor for phototherapy. The above-cited authors showed 
that the presence of meconium in the amniotic fluid, and 
foetal distress occur significantly more often if cholestasis 
occurs before the 34th week of pregnancy, regardless of the 
concentration of bile acids [18]. Our study fails to confirm the 
results obtained by the above authors. In our material, the 
average time of onset of both mild and severe cholestasis 
was the 33rd week of pregnancy. A study published by Oztas 
et al. showed that a TBA concentration of ≥ 51.00 μmol/L is 
a predictor of a low Apgar score in pregnant women with 
cholestasis. We did not confirm this relationship [19].
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Unfortunately, adverse outcomes of pregnancy com-
plicated by cholestasis may occur despite the treatment 
and reduction of the bile acid serum level [20]. Based on 
a randomised controlled trial (PITCHES), whose objective 
was to evaluate whether the application of ursodeoxycholic 
acid reduces the percentage of adverse perinatal outcomes 
in women with intrahepatic cholestasis of pregnancy, it was 
found not to have such an impact. Serious adverse events 
took place in both the treated group and the placebo group. 
In both groups, intrauterine foetal death occurred (twice in 
the placebo group and once in the UDCA- treated group). 
The stillbirths took place in the 35th and the 37th weeks of 
pregnancy [21].
The monitoring of pregnant woman with cholestasis 
should include systematic tests of bile acid serum level and 
active proceedings, involving elective early termination of 
pregnancy, in particular with high (> 100.00 μmol/L) con-
centrations of bile acids. Therefore, these women should 
be hospitalised in centres where bile acid concentrations 
are routinely tested, ready for immediate termination of 
pregnancy and specialist care for premature newborns.
The analysis we presented confirms that a higher TBA 
concentration is connected with adverse obstetric result in 
ICP patients. It may be concluded, following the analysis, that 
pregnant women with a TBA serum level over 40.00 μmol/L, 
have a worse prognosis regarding obstetric outcomes. The 
concentration of bile acids is a predictor of the occurrence 
of adverse perinatal outcomes, although the concentration 
of ALT and AST failed to show such a connection.
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